# Functional Characterization of POLE1 Variant Fibroblasts Reveals Replication Stress and Increased Sensitivity to Genotoxic Stress

**Authors:** Enas Khdeda, Nora Naumann-Bartsch, Nawres Khdeda, Giulia Cramer, Laura S. Hildebrand, Paula Schiller, Paul Julian Wagner, Franziska Fahrmeier, Ulrike Hüffmeier, Stefanie Corradini, Luitpold V. Distel, Lukas C. F. Kuhlmann

PMC · DOI: 10.3390/diseases14030092 · 2026-03-04

## TL;DR

This study shows that fibroblasts with POLE1 variants are more sensitive to DNA-damaging stress and experience replication issues.

## Contribution

First functional analysis of POLE1-variant fibroblasts from a compound-heterozygous patient, revealing replication stress and genotoxic sensitivity.

## Key findings

- POLE1-variant fibroblasts show reduced clonogenic survival after ionizing radiation compared to healthy controls.
- Increased chromosomal breakage and γH2AX foci suggest impaired DNA damage processing in these cells.
- Cells exhibit delayed proliferation, S phase accumulation, and heightened senescence under genotoxic stress.

## Abstract

Background/Objectives: DNA polymerase ε (Pol ε), encoded by POLE1, plays a pivotal role in high-fidelity DNA replication and in coordinating DNA repair. While pathogenic exonuclease-domain variants are well established in cancer, biallelic POLE1 variants remain largely unexplored in non-malignant human cells. Methods: Here, we analyzed primary fibroblasts derived from a skin biopsy of a compound-heterozygous patient carrying two POLE1 variants. Western blot analysis confirmed detectable Pol ε protein levels, indicating preserved protein expression despite the underlying variants. Results: Nevertheless, functional alterations were observed across multiple independent assays. Compared with healthy control fibroblasts, this patient-derived Pol ε fibroblast line exhibited reduced clonogenic survival following ionizing radiation. Surviving fractions were consistently lower across radiation doses from 2 to 4 Gy, with an approximately twofold reduction at 2 Gy and progressively greater differences at higher doses. The isoeffect dose corresponding to 10% survival was reduced relative to pooled control fibroblasts. In addition, chromosomal breakage was increased, supporting altered processing of radiation-induced DNA damage in this cellular model. Live-cell imaging and senescence assays revealed delayed proliferation and an increased proportion of senescent or senescence-like cells under baseline and genotoxic stress conditions, including enhanced senescence-associated β-galactosidase activity. Flow-cytometric analysis demonstrated S phase accumulation and G2/M arrest, consistent with replication stress and cell-cycle perturbation. Immunofluorescence staining revealed increased γH2AX foci, consistent with persistent DNA double strand breaks. RAD51 foci formation was not reduced; instead, increased RAD51 recruitment was observed under combined cisplatin and irradiation treatment, arguing against a primary defect in RAD51-mediated homologous recombination. POLE1-variant fibroblasts also showed impaired proliferative recovery, reduced wound closure, increased γH2AX accumulation following cisplatin exposure, suggesting heightened susceptibility to DNA crosslinking stress. Conclusions: Collectively, these findings provide the first functional characterization of a patient-derived POLE1-variant fibroblast cell line and indicate that altered Pol ε function may influence cellular responses to genotoxic stress. While based on primary fibroblasts from a single compound-heterozygous patient, validation in additional patient-derived or isogenic models will be required to determine the broader relevance of these findings.

## Linked entities

- **Genes:** POLE (DNA polymerase epsilon, catalytic subunit) [NCBI Gene 5426]
- **Proteins:** POLE (DNA polymerase epsilon, catalytic subunit), H2AXA (Histone superfamily protein), RAD51 (RAD51 recombinase)
- **Chemicals:** cisplatin (PubChem CID 5460033)

## Full-text entities

- **Genes:** ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, Pole (polymerase (DNA directed), epsilon) [NCBI Gene 18973], POLE3 (DNA polymerase epsilon 3, accessory subunit) [NCBI Gene 54107] {aka CHARAC17, CHRAC17, CHRAC2, YBL1, p17}, POLE4 (DNA polymerase epsilon 4, accessory subunit) [NCBI Gene 56655] {aka YHHQ1, p12}, Glb1 (galactosidase, beta 1) [NCBI Gene 12091] {aka Bge, Bgl, Bgl-e, Bgl-s, Bgl-t, Bgs}, Pole (DNA polymerase epsilon, catalytic subunit) [NCBI Gene 304573] {aka POLE1}, COL11A2 (collagen type XI alpha 2 chain) [NCBI Gene 1302] {aka DFNA13, DFNB53, FBCG2, HKE5, OSMEDA, OSMEDB}, POLE (DNA polymerase epsilon, catalytic subunit) [NCBI Gene 5426] {aka CRCS12, FILS, IMAGEI, POLE1}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}, Rad51 (RAD51 recombinase) [NCBI Gene 499870] {aka RGD1563603}, GLB1 (galactosidase beta 1) [NCBI Gene 2720] {aka EBP, ELNR1, MPS4B}, Anxa5 (annexin A5) [NCBI Gene 25673] {aka Anx5, CPB-I, LC5}, RPA1 (replication protein A1) [NCBI Gene 6117] {aka HSSB, MST075, PFBMFT6, REPA1, RF-A, RP-A}, RAD51 (RAD51 recombinase) [NCBI Gene 5888] {aka BRCC5, FANCR, HRAD51, HsRad51, HsT16930, MRMV2}
- **Diseases:** cytotoxicity (MESH:D064420), immune dysfunction (MESH:D007154), PPAP (MESH:D011125), colorectal cancer (MESH:D015179), immunodeficiency (MESH:D007153), livedo (MESH:D000090122), DNA breakage and instability (MESH:D019457), facial dysmorphism (MESH:C565579), endometrial and colorectal cancers (MESH:D016889), injury to (MESH:D014947), colorectal adenomas (MESH:D000236), Pol epsilon-deficiency (MESH:D001321), adrenal and skeletal anomalies (MESH:D000310), IMAGe syndrome (MESH:C564543), tumorigenesis (MESH:D063646), growth restriction (MESH:D005317), hereditary cancer syndrome (MESH:D009386), rectal carcinoma (MESH:D012004), necrosis (MESH:D009336), swelling (MESH:D004487), developmental abnormalities (MESH:D006130), syndromes (MESH:D013577), hypersensitivity (MESH:D004342), FILS syndrome (OMIM:615139), POLE1 deficiency (MESH:C566729), cancer (MESH:D009369)
- **Chemicals:** platinum (MESH:D010984), DAPI (MESH:C007293), acetic acid (MESH:D019342), Alexa Fluor 555 (MESH:C000608607), Alexa Fluor 488 (MESH:C000711379), Cis (MESH:D002945), streptomycin (MESH:D013307), PVDF (MESH:C024865), C12FDG (-), ethanol (MESH:D000431), potassium chloride (MESH:D011189), BrdU (MESH:D001973), CO2 (MESH:D002245), colcemid (MESH:D003703), Alexa Fluor 750 (MESH:C502599), polyacrylamide (MESH:C016679), Tris-glycine (MESH:C035647), Hoechst 33342 (MESH:C017807), NaCl (MESH:D012965), formaldehyde (MESH:D005557), 7-AAD (MESH:C025942), penicillin (MESH:D010406), methanol (MESH:D000432), aphidicolin (MESH:D016590), Bafilomycin A1 (MESH:C040929), methylene blue (MESH:D008751), PBS (MESH:D007854)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Mycoplasma (genus) [taxon 2093], Streptomyces griseus (species) [taxon 1911], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** c.51dup, c.4444+3A>G, P286R, V411L, c.2026 + 3G>T
- **Cell lines:** -7 — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_H340), SBLF-24 — Mus musculus (Mouse), Hybridoma (CVCL_C5HY), fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025677/full.md

---
Source: https://tomesphere.com/paper/PMC13025677